Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company’s all-human monoclonal antibodies target and neutralize human immunodeficiency virus and are being employed to produce anti-SARS-CoV-2 monoclonal antibodies for treating COVID-19. Its proprietary therapeutic is also being tested against Hepatitis A, B and C, Rheumatoid Arthritis, certain forms of cancer, rabies, influenza A and B, tetanus, and diphtheria. The company was founded on July 28, 2004 and is headquartered in Allen, TX.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company